The optimal use of PEG-Asparaginase in relapsed ALL—lessons from the ALLR3 Clinical Trial
Crossref DOI link: https://doi.org/10.1038/bcj.2014.26
Published Online: 2014-04-25
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Masurekar, A
Fong, C
Hussain, A
Revesz, T
Hoogerbrugge, P M
Love, S
Ciria, C
Parker, C
Krishnan, S
Saha, V
License valid from 2014-04-25
Article History
First Online: 25 April 2014
Competing interests
: The authors declare no conflict of interest.